Chemcon Speciality Chemicals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹65 Cr +21.9% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
CS

Chemcon Speciality Chemicals Ltd

Q1 FY27Chemicals & Petrochemicals

Chemcon Speciality Chemicals Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹66Cr
+24.2% YoY
−11.8% QoQ
Net profit
₹11Cr
+71.5% YoY
+72.1% QoQ
Margin
23.21%
+8.7 pp YoY
+11.4 pp QoQ

Based on Chemcon Speciality Chemicals Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹228
Market cap₹793 Cr
P/E28.1

The short version

Q1 FY27 Revenue from Operations: Rs. 66.5 Cr, up 24% YoY from Rs. 53.5 Cr in Q1 FY26 (Page 7). Quarterly EBITDA: ₹15.4 Cr (Q1 FY27), up 98% YoY from ₹7.7 Cr (Q1 FY26).

From Chemcon Speciality Chemicals Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1 FY27 Revenue from Operations: Rs. 66.5 Cr, up 24% YoY from Rs. 53.5 Cr in Q1 FY26 (Page 7).
  • Q1 FY27 Sales Volume: Total 3,302 MT (Organic Chemicals: 2,066 MT; Inorganic Chemicals: 1,236 MT) (Page 6).
  • Q1 FY26 Sales Volume: Total 3,434 MT (Organic Chemicals: 2,098 MT; Inorganic Chemicals: 1,336 MT), indicating a slight volume decline YoY (Page 6).
  • Outlook: The presentation states optimism about growth prospects driven by improving realizations, traction across newer products, and stronger customer engagement. It notes uncertainties due to global macroeconomic and geopolitical factors (Page 5).

Profitability & Margins

See what Chemcon Speciality Chemicals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Plan to add manufacturing capacity at the P11 unit dedicated to organic chemicals (Page 19, 17).
  • Capacity expansion aims to manufacture organic chemicals such as HMDS, CMIC, Bromobenzene, 2 Bromo (Page 17).
  • Timeline for new product launches: Bromobenzene business commenced in 2023, 2-Bromo business started in 2025 (Page 13).
  • FY22–24 period saw acquisition of Shivam Petrochem Industries and increased capacity via commissioning plants P7, P8, and P9 (Page 10).

2 more points from Chemcon Speciality Chemicals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Chemcon Speciality Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Specifically: - Financial and operational highlights focus on revenue, EBITDA, PAT, sales volume, product portfolio, capacity expansion, and growth drivers, but order-related metrics are absent.

Chemcon Speciality Chemicals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Chemcon Speciality Chemicals Ltd Q1 FY27 results — key figures

Chemcon Speciality Chemicals Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue6654+24.2%75-11.8%
Operating profit (EBITDA)158+98.6%9+73.8%
Operating margin23.21%14.52%+8.7 pp11.77%+11.4 pp
Profit before tax158+72.6%9+65.5%
Net profit (PAT)116+71.5%6+72.1%
EPS (₹)2.991.74+71.8%1.74+71.8%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹65 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Alufluoride (Q1 FY27)

    Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr

  • POCL Enterprises (Q1 FY27)

    466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto

  • Devson Catalyst (Q1 FY27)

    FY 2023-24: ₹5,577.59 Lakhs . Key investor presentation takeaways from Devson Catalyst Ltd's Q1 FY27 investor presentation — and how it ranks against sector pee

  • Ambani Orgochem (Q1 FY27)

    Financial highlights show Total Income in ₹ Lakhs: . Key investor presentation takeaways from Ambani Orgochem's Q1 FY27 investor presentation — and how it ranks

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Chemcon Speciality Chemicals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Chemcon Speciality Chemicals Ltd Q1 FY27 results?

Q1 FY27 Revenue from Operations: Rs. 66.5 Cr, up 24% YoY from Rs. 53.5 Cr in Q1 FY26 (Page 7). Quarterly EBITDA: ₹15.4 Cr (Q1 FY27), up 98% YoY from ₹7.7 Cr (Q1 FY26).

What is Chemcon Speciality Chemicals Ltd share price analysis?

Chemcon Speciality Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 28.1 with a market cap of ₹793 Cr. Investors should review the full earnings analysis for detailed insights.

Is Chemcon Speciality Chemicals Ltd planning capital expenditure?

Plan to add manufacturing capacity at the P11 unit dedicated to organic chemicals (Page 19, 17).

Keep Chemcon Speciality Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.